While these studies documented the successful outcomes of ITP patients switching between different TPO-RAs like eltrombopag, romiplostim, and avatrombopag, no data are currently available on switching from eltrombopag to hetrombopag specifically, warranting further investigation. Here, TPO is linked to autoimmune thrombocytopenic purpura.